Carcinoma, Non-Small-Cell Lung
"Carcinoma, Non-Small-Cell Lung" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
Descriptor ID |
D002289
|
MeSH Number(s) |
C04.588.894.797.520.109.220.249 C08.381.540.140.500 C08.785.520.100.220.500
|
Concept/Terms |
Carcinoma, Non-Small-Cell Lung- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Non Small Cell Lung
- Carcinomas, Non-Small-Cell Lung
- Lung Carcinoma, Non-Small-Cell
- Lung Carcinomas, Non-Small-Cell
- Non-Small-Cell Lung Carcinomas
- Nonsmall Cell Lung Cancer
- Non-Small-Cell Lung Carcinoma
- Non Small Cell Lung Carcinoma
- Carcinoma, Non-Small Cell Lung
- Non-Small Cell Lung Cancer
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Non-Small-Cell Lung".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Non-Small-Cell Lung".
This graph shows the total number of publications written about "Carcinoma, Non-Small-Cell Lung" by people in UAMS Profiles by year, and whether "Carcinoma, Non-Small-Cell Lung" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2024 | 12 | 0 | 12 | 2023 | 5 | 1 | 6 | 2022 | 4 | 0 | 4 | 2021 | 6 | 0 | 6 | 2020 | 5 | 1 | 6 | 2019 | 7 | 1 | 8 | 2018 | 10 | 0 | 10 | 2017 | 4 | 2 | 6 | 2016 | 6 | 0 | 6 | 2015 | 5 | 1 | 6 | 2014 | 3 | 1 | 4 | 2013 | 2 | 0 | 2 | 2012 | 1 | 0 | 1 | 2011 | 1 | 1 | 2 | 2010 | 2 | 1 | 3 | 2009 | 2 | 0 | 2 | 2008 | 5 | 1 | 6 | 2007 | 1 | 1 | 2 | 2006 | 2 | 1 | 3 | 2005 | 4 | 0 | 4 | 2004 | 2 | 0 | 2 | 2003 | 3 | 2 | 5 | 2002 | 0 | 1 | 1 | 2001 | 1 | 1 | 2 | 1996 | 4 | 0 | 4 | 1995 | 2 | 0 | 2 | 1993 | 1 | 0 | 1 | 1989 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Carcinoma, Non-Small-Cell Lung" by people in Profiles over the past ten years.
-
Jindani R, Rodriguez-Quintero JH, Kamel M, Zhu R, Vimolratana M, Chudgar N, Stiles B. Trends and Disparities in Robotic Surgery Utilization for Non-Small Cell Lung Cancer. J Surg Res. 2024 Oct; 302:24-32.
-
Rodriguez-Quintero JH, Ghanie A, Jindani R, Kamel MK, Zhu R, Vimolratana M, Chudgar NP, Stiles BM. Pneumonectomy for non-small cell lung cancer. A National Cancer Database analysis of geographic and temporal trends, outcomes, and associated factors. Surgery. 2024 Sep; 176(3):918-926.
-
Arnaoutakis K, Wan Y, Elliott J, Young M, Yin Y, Leventakos K, Lin HM, Dimou A. Real-World Treatment Patterns and Outcomes Across Three Lines of Therapy in Patients with ALK+ NSCLC. Adv Ther. 2024 Aug; 41(8):3217-3231.
-
Leighl NB, Akamatsu H, Lim SM, Cheng Y, Minchom AR, Marmarelis ME, Sanborn RE, Chih-Hsin Yang J, Liu B, John T, Massut? B, Spira AI, Lee SH, Wang J, Li J, Liu C, Novello S, Kondo M, Tamiya M, Korbenfeld E, Moskovitz M, Han JY, Alexander M, Joshi R, Felip E, Voon PJ, Danchaivijitr P, Hsu PC, Silva Melo Cruz FJ, Wehler T, Greillier L, Teixeira E, Nguyen D, Sabari JK, Qin A, Kowalski D, Sendur MAN, Xie J, Ghosh D, Alhadab A, Haddish-Berhane N, Clemens PL, Lorenzini P, Verheijen RB, Gamil M, Bauml JM, Baig M, Passaro A. Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study. J Clin Oncol. 2024 Oct 20; 42(30):3593-3605.
-
Halani V, Sharayah A, Beck B, Patolia S. "New Targets in Non-Small-Cell Lung Cancer"-RET, HER2, and KRAS. Am J Respir Crit Care Med. 2024 03 15; 209(6):748-750.
-
Taniguchi H, Chavan SS, Chow A, Chan JM, Mukae H, Rudin CM, Sen T. Role of CD38 in anti-tumor immunity of small cell lung cancer. Front Immunol. 2024; 15:1348982.
-
McCrury M, Swafford K, Shuttleworth SL, Mehdi SH, Acharya B, Saha D, Naceanceno K, Byrum SD, Storey AJ, Xu YZ, Doshier C, Patel V, Post GR, De Loose A, Rodriguez A, Shultz LD, Zhan F, Yoon D, Frett B, Kendrick S. Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma. Mol Cancer Ther. 2024 Mar 04; 23(3):316-329.
-
Rodriguez-Quintero JH, Elbahrawy MM, Montal AM, Jindani R, Vimolratana M, Kamel MK, Stiles BM, Chudgar NP. Minimally invasive surgery for clinical T4 non-small-cell lung cancer: national trends and outcomes. Eur J Cardiothorac Surg. 2024 Mar 01; 65(3).
-
Nasser N, Perez BA, Penagaricano JA, Caudell JJ, Oliver DE, Latifi K, Moros EG, Redler G. Technical feasibility of novel immunostimulatory low-dose radiation for polymetastatic disease with CBCT-based online adaptive and conventional approaches. J Appl Clin Med Phys. 2024 Jun; 25(6):e14303.
-
Rodriguez-Quintero JH, Jindani R, Kamel MK, Zhu R, Vimolratana M, Chudgar NP, Stiles BM. Resection of the Primary Tumor and Survival in Patients with Single-Site Synchronous Oligometastatic Non-Small Cell Lung Cancer: Propensity-Matched Analysis of the National Cancer Database. J Am Coll Surg. 2024 Jun 01; 238(6):1122-1136.
-
Jenkins SV, Shah S, Jamshidi-Parsian A, Mortazavi A, Kristian H, Boysen G, Vang KB, Griffin RJ, Rajaram N, Dings RPM. Acquired Radiation Resistance Induces Thiol-dependent Cisplatin Cross-resistance. Radiat Res. 2024 02 01; 201(2):174-187.
-
Rodriguez-Quintero JH, Kamel MK, Jindani R, Vimolratana M, Chudgar NP, Stiles BM. Sublobar resection is associated with less lymph nodes examined and lower delivery of adjuvant therapy in patients with 1.5- to 2.0-cm clinical IA2 non-small-cell lung cancer: a retrospective cohort study. Eur J Cardiothorac Surg. 2024 Jan 02; 65(1).
-
Zhou C, Solomon B, Loong HH, Park K, P?rol M, Arriola E, Novello S, Han B, Zhou J, Ardizzoni A, Mak MP, Santini FC, Elamin YY, Drilon A, Wolf J, Payakachat N, Uh MK, Rajakumar D, Han H, Puri T, Soldatenkova V, Lin AB, Lin BK, Goto K. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC. N Engl J Med. 2023 Nov 16; 389(20):1839-1850.
-
Elbahrawy MM, Kamel MK, Rodriguez-Quintero JH, Vimolratana M, Chudgar NP, Stiles BM. Association of socioeconomic factors with the receipt of neoadjuvant therapy for patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2024 Apr; 167(4):1458-1466.e4.
-
Mahashabde R, Bhatti SA, Martin BC, Painter JT, Rodriguez A, Ying J, Li C. Real-World Survival of First-Line Immune Checkpoint Inhibitor Treatment Versus Chemotherapy in Older Patients With Non-Small-Cell Lung Cancer and Synchronous Brain Metastases. JCO Oncol Pract. 2023 11; 19(11):1009-1019.
-
Rusthoven CG, Staley AW, Gao D, Yomo S, Bernhardt D, Wandrey N, El Shafie R, Kraemer A, Padilla O, Chiang V, Faramand AM, Palmer JD, Zacharia BE, Wegner RE, Hattangadi-Gluth JA, Levy A, Bernstein K, Mathieu D, Cagney DN, Chan MD, Grills IS, Braunstein S, Lee CC, Sheehan JP, Kluwe C, Patel S, Halasz LM, Andratschke N, Deibert CP, Verma V, Trifiletti DM, Cifarelli CP, Debus J, Combs SE, Sato Y, Higuchi Y, Aoyagi K, Brown PD, Alami V, Niranjan A, Lunsford LD, Kondziolka D, Camidge DR, Kavanagh BD, Robin TP, Serizawa T, Yamamoto M. Comparison of first-line radiosurgery for small-cell and non-small cell lung cancer brain metastases (CROSS-FIRE). J Natl Cancer Inst. 2023 08 08; 115(8):926-936.
-
Gupta N, Hanley MJ, Griffin RJ, Zhang P, Venkatakrishnan K, Sinha V. Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor. Clin Pharmacokinet. 2023 08; 62(8):1063-1079.
-
Pack A, Russell A, Kircher S, Weldon C, Bailey SC, Lockwood K, Marquart T, Afonso AS, Payakachat N, Wolf M. Current communication practices for biomarker testing in non-small cell lung cancer: Exploring patient and clinician perspectives. Patient Educ Couns. 2023 09; 114:107839.
-
Bilani N, Itani M, Soweid L, Iska S, Bertasi T, Bertasi R, Yaghi M, Mohanna M, Dominguez B, Saravia D, Alley E, Nahleh Z, Arteta-Bulos R. Geographic Origin may Affect Outcomes for Hispanic Patients with Non-Small Cell Lung Cancer in the United States. Clin Lung Cancer. 2023 09; 24(6):e219-e225.
-
Sivanesan E, Sanchez KR, Zhang C, He SQ, Linderoth B, Stephens KE, Raja SN, Guan Y. Spinal Cord Stimulation Increases Chemoefficacy and Prevents Paclitaxel-Induced Pain via CX3CL1. Neuromodulation. 2023 Jul; 26(5):938-949.
-
Khan S, Budamagunta V, Zhou D. Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies. Adv Cancer Res. 2023; 159:145-184.
-
Chow A, Uddin FZ, Liu M, Dobrin A, Nabet BY, Mangarin L, Lavin Y, Rizvi H, Tischfield SE, Quintanal-Villalonga A, Chan JM, Shah N, Allaj V, Manoj P, Mattar M, Meneses M, Landau R, Ward M, Kulick A, Kwong C, Wierzbicki M, Yavner J, Egger J, Chavan SS, Farillas A, Holland A, Sridhar H, Ciampricotti M, Hirschhorn D, Guan X, Richards AL, Heller G, Mansilla-Soto J, Sadelain M, Klebanoff CA, Hellmann MD, Sen T, de Stanchina E, Wolchok JD, Merghoub T, Rudin CM. The ectonucleotidase CD39 identifies tumor-reactive CD8+ T?cells predictive of immune checkpoint blockade efficacy in human lung cancer. Immunity. 2023 01 10; 56(1):93-106.e6.
-
Jee J, Lebow ES, Yeh R, Das JP, Namakydoust A, Paik PK, Chaft JE, Jayakumaran G, Rose Brannon A, Benayed R, Zehir A, Donoghue M, Schultz N, Chakravarty D, Kundra R, Madupuri R, Murciano-Goroff YR, Tu HY, Xu CR, Martinez A, Wilhelm C, Galle J, Daly B, Yu HA, Offin M, Hellmann MD, Lito P, Arbour KC, Zauderer MG, Kris MG, Ng KK, Eng J, Preeshagul I, Victoria Lai W, Fiore JJ, Iqbal A, Molena D, Rocco G, Park BJ, Lim LP, Li M, Tong-Li C, De Silva M, Chan DL, Diakos CI, Itchins M, Clarke S, Pavlakis N, Lee A, Rekhtman N, Chang J, Travis WD, Riely GJ, Solit DB, Gonen M, Rusch VW, Rimner A, Gomez D, Drilon A, Scher HI, Shah SP, Berger MF, Arcila ME, Ladanyi M, Levine RL, Shen R, Razavi P, Reis-Filho JS, Jones DR, Rudin CM, Isbell JM, Li BT. Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer. Nat Med. 2022 11; 28(11):2353-2363.
-
Kumar R, Castillero F, Bhandari S, Malapati S, Kloecker G. The Hispanic Paradox in Non-Small Cell Lung Cancer. Hematol Oncol Stem Cell Ther. 2022 Jun 01; 15(2):21-29.
-
Khan S, Wiegand J, Zhang P, Hu W, Thummuri D, Budamagunta V, Hua N, Jin L, Allegra CJ, Kopetz SE, Zajac-Kaye M, Kaye FJ, Zheng G, Zhou D. BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers. J Hematol Oncol. 2022 03 09; 15(1):23.
-
Kamel MK, Sholi AN, Harrison SW, Lee B, Port JL, Altorki NK, Stiles BM. Minimally Invasive Surgery for Lung Cancer Following Neoadjuvant Therapy in the United States. J Laparoendosc Adv Surg Tech A. 2022 Aug; 32(8):860-865.
-
Quintanal-Villalonga A, Taniguchi H, Zhan YA, Hasan MM, Chavan SS, Meng F, Uddin F, Allaj V, Manoj P, Shah NS, Chan JM, Ciampricotti M, Chow A, Offin M, Ray-Kirton J, Egger JD, Bhanot UK, Linkov I, Asher M, Roehrl MH, Ventura K, Qiu J, de Stanchina E, Chang JC, Rekhtman N, Houck-Loomis B, Koche RP, Yu HA, Sen T, Rudin CM. Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation. J Hematol Oncol. 2021 10 16; 14(1):170.
-
Li R, Roy A, Bice N, Kirby N, Fakhreddine M, Papanikolaou N. Managing tumor changes during radiotherapy using a deep learning model. Med Phys. 2021 Sep; 48(9):5152-5164.
-
Wu CE, Chang CF, Huang CY, Yang CT, Kuo CS, Hsu PC, Chang JW. Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study. BMC Cancer. 2021 Jul 27; 21(1):859.
-
Memmott RM, Wolfe AR, Carbone DP, Williams TM. Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors. J Thorac Oncol. 2021 07; 16(7):1086-1098.
-
Shafique MR, Fisher TL, Evans EE, Leonard JE, Pastore DRE, Mallow CL, Smith E, Mishra V, Schr?der A, Chin KM, Beck JT, Baumgart MA, Govindan R, Gabrail NY, Spira AI, Seetharamu N, Lou Y, Mansfield AS, Sanborn RE, Goldman JW, Zauderer M. A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2021 07 01; 27(13):3630-3640.
-
Gonzalvez F, Vincent S, Baker TE, Gould AE, Li S, Wardwell SD, Nadworny S, Ning Y, Zhang S, Huang WS, Hu Y, Li F, Greenfield MT, Zech SG, Das B, Narasimhan NI, Clackson T, Dalgarno D, Shakespeare WC, Fitzgerald M, Chouitar J, Griffin RJ, Liu S, Wong KK, Zhu X, Rivera VM. Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer. Cancer Discov. 2021 07; 11(7):1672-1687.
-
Del Valle L, Dai L, Lin HY, Lin Z, Chen J, Post SR, Qin Z. Role of EIF4G1 network in non-small cell lung cancers (NSCLC) cell survival and disease progression. J Cell Mol Med. 2021 03; 25(6):2795-2805.
-
Traver G, Sekhar KR, Crooks PA, Keeney DS, Freeman ML. Targeting NPM1 in irradiated cells inhibits NPM1 binding to RAD51, RAD51 foci formation and radiosensitizes NSCLC. Cancer Lett. 2021 03 01; 500:220-227.
-
Jin J, Robeson H, Fagan P, Orloff MS. Association of PARP1-specific polymorphisms and haplotypes with non-small cell lung cancer subtypes. PLoS One. 2020; 15(12):e0243509.
-
Desai D, Narayanasamy G, Bimali M, Cordrey I, Elasmar H, Srinivasan S, Johnson EL. Cleaning the dose falloff in lung SBRT plan. J Appl Clin Med Phys. 2021 Jan; 22(1):100-108.
-
Ott PA, Hu-Lieskovan S, Chmielowski B, Govindan R, Naing A, Bhardwaj N, Margolin K, Awad MM, Hellmann MD, Lin JJ, Friedlander T, Bushway ME, Balogh KN, Sciuto TE, Kohler V, Turnbull SJ, Besada R, Curran RR, Trapp B, Scherer J, Poran A, Harjanto D, Barthelme D, Ting YS, Dong JZ, Ware Y, Huang Y, Huang Z, Wanamaker A, Cleary LD, Moles MA, Manson K, Greshock J, Khondker ZS, Fritsch E, Rooney MS, DeMario M, Gaynor RB, Srinivasan L. A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell. 2020 10 15; 183(2):347-362.e24.
-
Patel MA, Fazli Y, Sivakumar S, Dennis C, Maraboyina S, Prabhu AV, Kim T. Brachytherapy vs external beam therapy among NSCLC patients undergoing limited surgical resection. J Cancer Res Clin Oncol. 2021 Mar; 147(3):853-861.
-
Chu CH, Chiu TH, Wang CC, Chang WC, Huang AC, Liu CY, Wang CL, Ko HW, Chung FT, Hsu PC, Guo YK, Kuo CS, Yang CT. Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancer. Thorac Cancer. 2020 06; 11(6):1541-1549.
-
Weiss JM, Pennell N, Deal AM, Morgensztern D, Bradford DS, Crane J, West HJ, Lee C, Pecot C, Stevenson JP, Irvin W, Socinski M, Stinchcombe T, Villaruz LC, Muss HB. Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy. Cancer. 2020 03 01; 126(5):1060-1067.
-
Cifarelli CP, Brehmer S, Vargo JA, Hack JD, Kahl KH, Sarria-Vargas G, Giordano FA. Intraoperative radiotherapy (IORT) for surgically resected brain metastases: outcome analysis of an international cooperative study. J Neurooncol. 2019 Nov; 145(2):391-397.
-
Huang SH, Huang AC, Wang CC, Chang WC, Liu CY, Pavlidis S, Ko HW, Chung FT, Hsu PC, Guo YK, Kuo CS, Yang CT. Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control. Thorac Cancer. 2019 12; 10(12):2274-2281.
-
Chua IS, Zachariah F, Dale W, Feliciano J, Hanson L, Blackhall L, Quest T, Curseen K, Grey C, Rhodes R, Shoemaker L, Silveira M, Fischer S, O'Mahony S, Leventakos K, Trotter C, Sereno I, Kamdar M, Temel J, Greer JA. Early Integrated Telehealth versus In-Person Palliative Care for Patients with Advanced Lung Cancer: A Study Protocol. J Palliat Med. 2019 09; 22(S1):7-19.
-
Hsu PC, Chang JW, Wang CC, Wu CT, Lin YC, Wang CL, Lin TY, Li SH, Wu YC, Kuo SC, Yang CT, Liu CY, Chen CH. Oral vinorelbine plus cisplatin with concomitant radiotherapy as induction therapy for stage III non-small cell lung cancer: Results of a single-arm prospective cohort study. Thorac Cancer. 2019 08; 10(8):1683-1691.
-
Yang F, Shao C, Wei K, Jing X, Qin Z, Shi Y, Shu Y, Shen H. miR-942 promotes tumor migration, invasion, and angiogenesis by regulating EMT via BARX2 in non-small-cell lung cancer. J Cell Physiol. 2019 12; 234(12):23596-23607.
-
Ying J, Zhou D, Gu T, Huang J, Liu H. Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy. BMC Cancer. 2019 Mar 29; 19(1):288.
-
Sloan L, Romo CG, Hales RK. Hemifacial Hyperhidrosis in a Patient With an Apical Non-Small Cell Lung Cancer. JAMA Oncol. 2019 03 01; 5(3):422-423.
-
Mohindra P, Sawant A, Griffin RJ, Lamichhane N, Vlashi E, Xu-Welliver M, Dominello M, Joiner MC, Burmeister J. Three discipline collaborative radiation therapy (3DCRT) special debate: I would treat all early-stage NSCLC patients with SBRT. J Appl Clin Med Phys. 2019 03; 20(3):7-13.
-
Dresler C, Warren GW, Arenberg D, Yang P, Steliga MA, Cummings KM, Stone E, Jassem J. Indeed, Nuance Matters. J Thorac Oncol. 2019 01; 14(1):e16-e17.
-
Omofoye OA, Barnett R, Lau W, Trembath D, Jordan JD, Sasaki-Adams DM. Neoplastic Cerebral Aneurysm From Metastatic Nonsmall Cell Lung Carcinoma: Case Report and Literature Review. Neurosurgery. 2018 12 01; 83(6):E221-E225.
-
Altorki NK, Wang X, Wigle D, Gu L, Darling G, Ashrafi AS, Landrenau R, Miller D, Liberman M, Jones DR, Keenan R, Conti M, Wright G, Veit LJ, Ramalingam SS, Kamel M, Pass HI, Mitchell JD, Stinchcombe T, Vokes E, Kohman LJ. Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503). Lancet Respir Med. 2018 12; 6(12):915-924.
-
Parikh K, Kumar A, Ahmed J, Anwar A, Puccio C, Chun H, Fanucchi M, Lim SH. Peripheral monocytes and neutrophils predict response to immune checkpoint inhibitors in patients with metastatic non-small cell lung cancer. Cancer Immunol Immunother. 2018 Sep; 67(9):1365-1370.
-
Limviphuvadh V, Tan CS, Konishi F, Jenjaroenpun P, Xiang JS, Kremenska Y, Mu YS, Syn N, Lee SC, Soo RA, Eisenhaber F, Maurer-Stroh S, Yong WP. Discovering novel SNPs that are correlated with patient outcome in a Singaporean cancer patient cohort treated with gemcitabine-based chemotherapy. BMC Cancer. 2018 May 11; 18(1):555.
-
Yang F, Wei K, Qin Z, Liu W, Shao C, Wang C, Ma L, Xie M, Shu Y, Shen H. MiR-598 Suppresses Invasion and Migration by Negative Regulation of Derlin-1 and Epithelial-Mesenchymal Transition in Non-Small Cell Lung Cancer. Cell Physiol Biochem. 2018; 47(1):245-256.
-
Dresler C, Warren GW, Arenberg D, Yang P, Steliga MA, Cummings KM, Stone E, Jassem J. "Teachable Moment" Interventions in Lung Cancer: Why Action Matters. J Thorac Oncol. 2018 05; 13(5):603-605.
-
Funkhouser WK, Hayes DN, Moore DT, Funkhouser WK, Fine JP, Jo H, Nikolaishvilli-Feinberg N, Eeva M, Grilley-Olson JE, Banks PM, Graziano P, Boswell EL, Elmberger G, Raparia K, Hart CF, Sholl LM, Nolan NJ, Fritchie KJ, Pouagare E, Allen TC, Volmar KE, Biddinger PW, Kleven DT, Papez MJ, Spencer DV, Rekhtman N, Mino-Kenudson M, Hariri L, Driver B, Cagle PT. Interpathologist Diagnostic Agreement for Non-Small Cell Lung Carcinomas Using Current and Recent Classifications. Arch Pathol Lab Med. 2018 12; 142(12):1537-1548.
-
Rahouma M, Kamel M, Narula N, Nasar A, Harrison S, Lee B, Stiles B, Altorki NK, Port JL. Pulmonary sarcomatoid carcinoma: an analysis of a rare cancer from the Surveillance, Epidemiology, and End Results database. Eur J Cardiothorac Surg. 2018 04 01; 53(4):828-834.
-
Del C Monroig-Bosque P, Driver B, Morales-Rosado JA, Deavers M, Tacha D, Bernicker E, Cagle PT, Miller RA. Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma. Arch Pathol Lab Med. 2018 11; 142(11):1388-1393.
-
Al Hadidi S. Delayed Adjuvant Chemotherapy and Survival After Lung Cancer Surgery. JAMA Oncol. 2018 02 01; 4(2):262.
-
Maarouf M, Alexander C, Shi VY. Nivolumab reactivation of hypertrophic lichen planus, a case report and review of published literature. Dermatol Online J. 2018 Jan 15; 24(1).
-
Dai L, Smith CD, Foroozesh M, Miele L, Qin Z. The sphingosine kinase 2 inhibitor ABC294640 displays anti-non-small cell lung cancer activities in vitro and in vivo. Int J Cancer. 2018 05 15; 142(10):2153-2162.
-
Page RD, Argento AC, Nash DB, Skoufalos A, Schaefer ES. The Role of Proteomic Testing in Improving Prognosis And Care Planning Quality Measures for Lung Cancer. Manag Care. 2017 09; 26(9):37-47.
-
Driver BR, Miller RA, Miller T, Deavers M, Gorman B, Mody D, Ge Y, Barrios R, Bernicker E, Kim M, Cagle PT. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas. Arch Pathol Lab Med. 2017 Nov; 141(11):1529-1532.
-
Nia ES, Garland LL, Eshghi N, Nia BB, Avery RJ, Kuo PH. Incidence of Brain Metastases on Follow-up 18F-FDG PET/CT Scans of Non-Small Cell Lung Cancer Patients: Should We Include the Brain? J Nucl Med Technol. 2017 Sep; 45(3):193-197.
-
Modiri A, Sabouri P, Gu X, Timmerman R, Sawant A. Inversed-Planned Respiratory Phase Gating in?Lung Conformal Radiation Therapy. Int J Radiat Oncol Biol Phys. 2017 10 01; 99(2):317-324.
-
Ghaly G, Rahouma M, Kamel MK, Nasar A, Harrison S, Nguyen AB, Port J, Stiles BM, Altorki NK, Lee PC. Clinical Predictors of Nodal Metastases in Peripherally Clinical T1a N0 Non-Small Cell Lung Cancer. Ann Thorac Surg. 2017 Oct; 104(4):1153-1158.
-
Moore KN, Borghaei H, O'Malley DM, Jeong W, Seward SM, Bauer TM, Perez RP, Matulonis UA, Running KL, Zhang X, Ponte JF, Ruiz-Soto R, Birrer MJ. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor a-targeting antibody-drug conjugate, in patients with solid tumors. Cancer. 2017 Aug 15; 123(16):3080-3087.
-
Stiles BM, Kamel MK, Nasar A, Harrison S, Nguyen AB, Lee P, Port JL, Altorki NK. The importance of lymph node dissection accompanying wedge resection for clinical stage IA lung cancer. Eur J Cardiothorac Surg. 2017 03 01; 51(3):511-517.
-
Kamel MK, Nasar A, Stiles BM, Altorki NK, Port JL. Video-Assisted Thoracoscopic Lobectomy Is the Preferred Approach Following Induction Chemotherapy. J Laparoendosc Adv Surg Tech A. 2017 May; 27(5):495-500.
-
Kamel MK, Rahouma M, Ghaly G, Nasar A, Port JL, Stiles BM, Nguyen AB, Altorki NK, Lee PC. Clinical Predictors of Persistent Mediastinal Nodal Disease After Induction Therapy for Stage IIIA N2 Non-Small Cell Lung Cancer. Ann Thorac Surg. 2017 Jan; 103(1):281-286.
-
Altorki NK, Kamel MK, Narula N, Ghaly G, Nasar A, Rahouma M, Lee PC, Port JL, Stiles BM. Anatomical Segmentectomy and Wedge Resections Are Associated with Comparable Outcomes for Patients with Small cT1N0 Non-Small Cell Lung Cancer. J Thorac Oncol. 2016 11; 11(11):1984-1992.
-
Pokhrel D, Sood S, Badkul R, Jiang H, McClinton C, Lominska C, Kumar P, Wang F. Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy. J Appl Clin Med Phys. 2016 05 08; 17(3):277-293.
-
Engelen MP, Safar AM, Bartter T, Koeman F, Deutz NE. Reduced arginine availability and nitric oxide synthesis?in cancer?is related to impaired endogenous arginine synthesis. Clin Sci (Lond). 2016 07 01; 130(14):1185-95.
-
Shukla S, Sinha S, Khan S, Kumar S, Singh K, Mitra K, Maurya R, Meeran SM. Cucurbitacin B inhibits the stemness and metastatic abilities of NSCLC via downregulation of canonical Wnt/?-catenin signaling axis. Sci Rep. 2016 Feb 24; 6:21860.
-
Shafirstein G, Battoo A, Harris K, Baumann H, Gollnick SO, Lindenmann J, Nwogu CE. Photodynamic Therapy of Non-Small Cell Lung Cancer. Narrative Review and Future Directions. Ann Am Thorac Soc. 2016 Feb; 13(2):265-75.
-
Liang X, Penagaricano J, Zheng D, Morrill S, Zhang X, Corry P, Griffin RJ, Han EY, Hardee M, Ratanatharathom V. Radiobiological impact of dose calculation algorithms on biologically optimized IMRT lung stereotactic body radiation therapy plans. Radiat Oncol. 2016 Jan 22; 11:10.
-
Lee PC, Kamel M, Nasar A, Ghaly G, Port JL, Paul S, Stiles BM, Andrews WG, Altorki NK. Lobectomy for Non-Small Cell Lung Cancer by Video-Assisted Thoracic Surgery: Effects of Cumulative Institutional Experience on Adequacy of Lymphadenectomy. Ann Thorac Surg. 2016 Mar; 101(3):1116-22.
-
Driver BR, Portier BP, Mody DR, Deavers M, Bernicker EH, Kim MP, Teh BS, Santacruz JF, Kopas L, Munden RF, Cagle PT. Next-Generation Sequencing of a Cohort of Pulmonary Large Cell Carcinomas Reclassified by World Health Organization 2015 Criteria. Arch Pathol Lab Med. 2016 Apr; 140(4):312-7.
-
Ghaly G, Kamel M, Nasar A, Paul S, Lee PC, Port JL, Stiles BM, Altorki NK. Video-Assisted Thoracoscopic Surgery Is a Safe and Effective Alternative to Thoracotomy for Anatomical Segmentectomy in Patients With Clinical Stage I Non-Small Cell Lung Cancer. Ann Thorac Surg. 2016 Feb; 101(2):465-72; discussion 472.
-
Weng DY, Chen J, Taslim C, Hsu PC, Marian C, David SP, Loffredo CA, Shields PG. Persistent alterations of gene expression profiling of human peripheral blood mononuclear cells from smokers. Mol Carcinog. 2016 10; 55(10):1424-37.
-
Engelen MPKJ, Safar AM, Bartter T, Koeman F, Deutz NEP. High anabolic potential of essential amino acid mixtures in advanced nonsmall cell lung cancer. Ann Oncol. 2015 Sep; 26(9):1960-1966.
-
Shukla S, Khan S, Kumar S, Sinha S, Farhan M, Bora HK, Maurya R, Meeran SM. Cucurbitacin B Alters the Expression of Tumor-Related Genes by Epigenetic Modifications in NSCLC and Inhibits NNK-Induced Lung Tumorigenesis. Cancer Prev Res (Phila). 2015 Jun; 8(6):552-62.
-
Arnaoutakis K. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2015 02 12; 372(7):683.
|
People People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|